Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Global pharmaceutical company Mylan has inked an exclusive agreement to distribute Zyomyx's, a California-based private diagnostic firm, point-of-care (POC) CD4 T-cell count test used in the treatment of HIV/AIDS in the developing countries.
Subscribe to our email newsletter
Based on the terms of the distribution and supply agreement, combined financing of both Mylan and the Bill & Melinda Gates Foundation amounts to $12m in investments, with nearly $6m being Mylan’s contribution.
Zyomyx will supply the POC CD4 test to Mylan, and in exchange Mylan will pay development and commercial milestones and a share of profits to Zyomyx for the exclusive rights to distribute the POC CD4 test in Africa, Asia, South America and Central and the Caribbean Islands.
CD4 count testing is a critical diagnostic component in treating HIV/AIDS, which helps medical professionals to decide when to start and/or alter HIV treatment.
Currently in final stages of development, the Zyomyx POC CD4 test is likely to be rolled out in the short-term, pending receipt of concerned regulatory approvals.
Developed using Zyomyx’s breakthrough diagnostic platform, the Zyomyx CD4 count provides results in less than 10 minutes with minimal training.
Mylan CEO Heather Bresch said that the collaboration will ensure better treatment by improving access to treatment of HIV in the developing world by enabling rapid, low-cost testing of patients in any location.
It will provide an easy-to-use, low-cost test to the people residing in the developing countries, who can afford expensive test and medicines.
A global access commitment has also been worked out with Bill & Melinda Gates Foundation, to ensure that the Zyomyx POC CD4 technology is available and accessible at a reasonable price in high burden HIV countries.